In treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor-α agents (anti-TNF-α), obesity has been suspected as a cause of accelerated loss of response (LOR). We sought to determine whether overweight IBD patients have accelerated LOR when treated with anti-TNF-α agents, compared with normal weight IBD patients.
INTRODUCTION
The introduction of anti-tumor necrosis factor-α (anti-TNF-α) agents in the late 1990s has revolutionized the management of inflammatory bowel disease (IBD). Unfortunately, 13%-40% of IBD patients are primary nonresponders to anti-TNF-α agents, and approximately one-third of patients will lose response over time. [1] [2] [3] [4] [5] [6] Obesity has been suggested to be a predictor for loss of response (LOR). However, this has mostly been studied in other autoimmune diseases such as rheumatoid arthritis [7] [8] [9] and spondyloarthritis. 10, 11 In the case of IBD, only a few smaller studies have addressed this issue directly, some of which suggest that obesity is associated with accelerated LOR. [12] [13] [14] There is no consensus on whether this association exists both for weight-adjusted anti-TNF-α agents-for example, infliximab (IFX)-and for agents where dosing is fixed, for example, adalimumab (ADA). [12] [13] [14] Correspondingly, there is no consensus on whether obesity is a predictor of an adverse prognosis in IBD. [15] [16] [17] [18] [19] In a Danish cohort of IBD patients treated with anti-TNF-α agents, we sought to determine whether overweight patients have accelerated LOR for anti-TNF-α agents, compared with normal weight patients.
METHODS
This is an observational cohort study of adult IBD patients treated with anti-TNF-α agents at the Department of Medical Gastroenterology, Odense University Hospital, Denmark, in the period between January 1, 2003, and December 31, 2015. Patients were classified according to body mass index (BMI): underweight (BMI < 18.5), normal weight (BMI, 18.5-25), overweight (BMI, [25] [26] [27] [28] [29] [30] , and obese (BMI > 30). 20 We compared time to LOR between these groups. Patients were included if they were at least age 18 years at treatment initiation and were treated for Crohn's disease (CD) or ulcerative colitis (UC) with anti-TNF-α agents. In the analysis, we excluded patients with no recorded information on weight or height, patients with BMI <18.5, patients who had previously received anti-TNF-α agent treatment, patients classified as primary nonresponders to anti-TNF-α therapy, and patients who discontinued treatment during or immediately after induction for other reasons. We defined primary nonresponse as stop of treatment due to lack of effect within 16 weeks after the first treatment. 21 We identified the cohort by manually reviewing medical records, retrieving information on IBD subtype, course of the disease, date of anti-TNF-α agent treatment initiation, choice of anti-TNF-α agent, treatment response, time and reason for discontinuation, treatment intensification (ie, dose increase or reduced treatment interval), surgery due to IBD, smoking status, sex, height, age, and weight at treatment initiation. For all patients, we retrieved information on the extent, behaviour, and activity of the disease, following the Montreal classification. 22 We obtained data on concurrent prescription medication from the Odense Pharmaco-Epidemiological Database (OPED), which is a database on subsidized prescriptions for the inhabitants of the Region of Southern Denmark. 23 Linkage of the data was performed using the personal identification number, which is a unique identifier assigned to all Danish individuals. 24 We obtained prescription data on glucocorticoids for systemic use, 5-ASA, azathioprine, and methotrexate. The main outcome was time to LOR after initiation of anti-TNF-α treatment, with LOR defined by dose increase, reduced treatment interval, surgery due to IBD, or discontinuation of anti-TNF-α agent due to nonsatisfactory treatment response. If a patient experiences a flare in the disease during anti-TNF-α agent treatment, the standard approach is to increase the dose or to reduce the treatment interval. 21 Therefore, we included dose increase and reduction of treatment interval as proxies for LOR. Time to LOR was calculated from date of first treatment with anti-TNF-α agent to first date with 1 of the events mentioned above. Using Cox regression, we calculated hazard ratios for the 3 BMI categories: normal weight, overweight, and obese, with the normal weight group as the reference. In further analysis, we adjusted for age, sex, and smoking status. Finally, we performed an extended analysis with adjustment for age, sex, smoking status, concurrent medication, former bowel resection, IBD subtype, and type of anti-TNF-α.
All analyses were performed using STATA, release 14.1 (StataCorp, College Station, TX, USA).
Ethical Considerations
The Danish Data Protection Agency approved the study (file number 2012-58-0018). The Danish Health Authority approved the study (case number 3-3013-1116/2). Approval from the Ethics Committee was not required according to Danish law.
RESULTS
We identified a cohort of 374 patients. Forty-four patients (12%) were excluded due to primary nonresponse to treatment. In 57 patients (15%), treatment was discontinued during or just after completing induction treatment for reasons other than nonresponse. These 57 patients were mostly treated when experience with anti-TNF-α treatment was limited and maintenance treatment was not yet established as routine practice. In 37 patients (10%), we had no information on BMI. Eighteen patients were excluded due to BMI <18.5. Two hundred ten patients were eligible for analysis ( Fig. 1) , with a median follow-up (interquartile range) of 9.6 (5.4-15.6) months. At initiation of anti-TNF-α treatment, 54% of the patients were normal weight, 24% overweight, and 21% obese, (Table 1) . IFX was used in 86% of patients, and ADA was used in 14% of patients (Table 1) . Among the 210 patients included in the analysis, 92 patients (44%) experienced LOR during 247 person-years at risk. The LOR was distributed among the BMI groups as follows: normal weight 53 (47%), overweight 17 (33%), and obese 22 (49%) ( Table 1 ). In 43 (20%) patients, treatment was discontinued due to side effects or infection. Thirty-nine patients (19%) discontinued treatment due to long-lasting remission. These subjects were censored in the survival analysis.
Hazard ratios for overweight and obese patients were 0.90 (95% confidence interval [CI], 0.52-1.55) and 1.13 (95% CI, 0.69-1.87) compared with the normal weight category. Thus, none of the BMI categories showed a statistically significantly higher hazard ratio of LOR, compared with the normal weight category. Figure 2 shows the Kaplan-Meier plot of the 4 BMI categories from initiation of anti-TNF-α treatment to LOR. Adjusting for sex, age, and smoking status yielded only minor changes to the estimates, and the same applied to an extended adjustment ( Table 2) .
Stratification by IBD subtype and by type of anti-TNF-α treatment did not alter the results substantially, except for obese patients treated for UC, who had a crude hazard of 2.38 (95% CI, 1.05-5.42) ( Table 2) . We redid the subgroup analyses and included phenotype and severity for Crohn's disease and ulcerative colitis. This did not produce any discernible change in results.
The IFX subgroup showed a trend toward decreased time to LOR with increasing BMI, and this trend was more pronounced in the adjusted analyses (Table 2) .
In a post hoc analysis, we included the patients categorized as primary nonresponders (PNR). This yielded only negligible changes of the results. The abovementioned trend in the IFX group was more pronounced when including PNR patients, but only reached statistical significance in the extended adjustment (Table 3 ; Supplementary Data). Also, we established a secondary end point in which LOR was based purely on patients undergoing surgery. We analyzed time from initiation of treatment to first surgery, either during treatment or after treatment discontinuation, regardless of reason for discontinuation. This produced 46 events of LOR (surgery) during 398 person-years at risk, the surgery events were distributed uniformly between BMI groups with crude hazard ratios of 1.01 (95% CI, 0.49-2.11) for overweight and 1.04 (95% CI, 0.50-2.16) for obese
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patients, compared with the normal weight group. Lastly, we evaluated the association between anti TNF exposure and LOR per unit of BMI, with BMI as a continuous variable instead of BMI categories. This approach did not reveal any new association between BMI and LOR, with each 1-point increase in BMI giving crude hazard ratios of 1.01 (95% CI, 0.97-1.04) for all IBD patients, 0.97 (95% CI, 0.93-1.02) for CD patients, and 1.08 (95% CI, 1.00-1.17) for UC patients. After adjustment for possible confounders, the UC patients had a hazard ratio of 1.11 (95% CI, 1.02-1.20) for each 1-point BMI increase.
DISCUSSION
In this large cohort study of adult IBD patients treated with anti-TNF-α agents, we found no overall association between overweight or obesity and time to LOR. However, when stratifying the patients in the disease entities UC and CD, we found an increased hazard ratio for LOR in obese UC patients. Identical results were found when the association was evaluated with BMI as a continuous variable instead of BMI categories.
For a drug with conventional first-order kinetics, the maintenance dose is independent of the volume of distribution; that is, obese patients should have the same daily dose in mg as normal weight patients. However, the pharmacokinetic properties of anti-TNF-α agents in IBD patients are extremely complex, and possibly even more so in obesity. If indeed obesity plays a role in response to anti-TNF-α agents, possible explanations include a pro-inflammatory role of the adipose tissue. [25] [26] [27] [28] We did not routinely perform therapeutic drug monitoring (TDM) on patients treated with anti-TNF-α agents. TDM data could have been useful in this study to evaluate the effect of BMI on trough levels.
Having a high BMI does not necessarily mean having a large amount of body fat, and this study has no data on body composition, that is, rate of body fat vs fat-free body mass; we only had access to data on BMI. A better test of the obesity-inflammation hypothesis would be a prospective study including measurements of body composition of the individual patient before treatment initiation.
We used dose escalation, that is, increased dose or decreased time between treatments, as a proxy marker for LOR. Dose escalation was based on a clinical assessment of whether the patient was losing treatment response. Thus, the validity of dose escalation as a proxy for LOR rests on the quality of the clinical assessment of We defined concurrent medication as having retrieved a prescription within the last 3 months before initiation of anti-TNF-α treatment. the physician who makes the decision of treatment intensification. Twelve percent of our patients were classified as primary nonresponders, and 43% experienced LOR, the first number being on the low end and the second on the high end of estimates from previously published studies. 29, 30 Inclusion of primary nonresponders in the main analysis did not alter the results noticeably. 1 (1) Only 4 patients were treated for more than 4.5 years without experiencing an LOR; for these 4 patients, we censored the plot at 4.5 years after treatment initiation to avoid a disproportionate look of the graph. The small number of ADA patients could not bear the entire analysis, and the numbers listed should be considered with caution.
A large portion of ADA patients were excluded due to missing data on BMI. Thus we were only able to include 30 patients treated with ADA; 4 of these were overweight, and 8 were obese. The results from the subgroup analysis of the ADA patients should therefore be considered with caution.
A secondary end point consisting solely of time to surgery after initiation of treatment showed no difference between BMI groups.
As the median follow-up of this study was <1 year, we were not able to report the long-term impact of obesity on treatment success.
Previous studies on the effect of obesity on IBD-related therapy have found obese IBD patients to be at higher risk of dose escalation in treatment with TNF-α agents [12] [13] [14] ; in this study, we did not reproduce these results. We did not find consistent evidence suggesting that overweight patients should receive different treatment than the average normal weight patient, or that these patients should primarily be treated with weight-adjusted anti-TNF-α agents. However, in the subgroups of UC patients and patients treated with IFX, we saw a trend toward accelerated LOR with increasing BMI, but only in the small subgroup of obese UC patients did this association reach statistical significance. This could very well be a chance association, given the multiple statistical comparisons made in this study. That this subgroup should have an unusual response pattern was not a prespecified hypothesis and should be corroborated in other studies before any inferences can be made.
CONCLUSION
In this cohort of Danish IBD patients treated with anti-TNF-α agents, in which 86% of patients were treated with infliximab and 14% with adalimumab, we found no overall association between overweight/obesity and loss of response compared with normal weight patients with identical treatment regimens.
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